Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Highly Accessed Poster presentation

Primary bone lymphoma

C Pissarro C Azevedo1*, P José AFF Tavares2, M Isabel P Portela1, A José LCP Santos2 and J Manuel PS Casanova2

Author Affiliations

1 Department of Medical Oncology, Portuguese Oncology Institute of Coimbra, Coimbra, Portugal

2 Bone and Soft Tissue Tumor Unit, Coimbra University Hospital, Coimbra, Portugal

For all author emails, please log on.

BMC Proceedings 2010, 4(Suppl 2):P8  doi:10.1186/1753-6561-4-S2-P8

The electronic version of this article is the complete one and can be found online at:

Published:24 September 2010

© 2010 Azevedo et al; licensee BioMed Central Ltd.


Primary bone lymphoma (PBL) accounts for 3% of all primary bone malignancies [1] and represents <2% of all lymphomas in adults [2].

Material and methods

Retrospective review of 25 patients with PBL treated at a single institution between 1995 and 2010.


14 patients were female. The median age was 63 years (30-90). 13 had localized disease. The tumor had an axial location in 20 patients (80%). 6 patients presented with a pathologic fracture. The histological type was Non-Hodgkin Lymphoma B in all patients. There were 18 high grade lymphomas. According to the IPI, 8 cases (32%) were classified as low risk, 11 cases (44%) as intermediate risk and 6 (24%) as high risk. All patients received chemotherapy. 17 patients were treated with radiotherapy to a total dose that varied from 15 to 50 Gy. 7 patients underwent surgical treatment. The median follow-up was 12 months (1-121). Recurrence of the disease was seen in 3 patients. 9 patients had disease progression. With regard to the status of the patients: 8 patients are continuously disease free; 3 patients are alive with disease; 10 patients died of the disease; 2 patients died of other cause. The 10-year overall survival rate was 45%. The 5-year survival rate was 85% for low-risk IPI vs 35% for intermediate-risk IPI vs 18% for high-risk IPI.


Combined modality treatment results in good survival rates in patients with low-risk and intermediate-risk PBL.


  1. Limb D, Dreghorn C, Murphy JK, Mannion R: Primary lymphoma of bone.

    Int Orthop 1994, 18:180-183. PubMed Abstract | Publisher Full Text OpenURL

  2. Dubey P, Ha CS, Besa PC, Fuller L, Cabanillas F, Murray J, Hess MA, Cox JD: Localized primary malignant lymphoma of bone.

    Int J Radiat Oncol Biol Phys 1997, 37:1087-1093. PubMed Abstract | Publisher Full Text OpenURL